Alimera, Knight seek Canadian regulatory nod for Iluvien intravitreal implant

Alimera Sciences (NSDQ:ALIM) and Knight Therapeutics (TSE:GUD) said today that Health Canada accepted the companies’ New Drug Application for its intravitreal implant, Iluvien.

The FDA approved Atlanta-based Alimera’s sustained release intravitreal implant in 2014 to treat diabetic macular edema in patients who have been previously treated with corticosteroids and did not have a clinically significant rise in intraocular pressure.

Get the full story at our sister site, Drug Delivery Business News.

The post Alimera, Knight seek Canadian regulatory nod for Iluvien intravitreal implant appeared first on MassDevice.

from MassDevice http://ift.tt/2lFIR0Y